Navigation Links
Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
Date:4/24/2009

SEATTLE, April 24 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the following data presentations taking place at the American Urological Association's (AUA) Annual Meeting in Chicago, as well as a Dendreon-sponsored IMPACT data webcast conference call:

  • April 28, 2009, 2:20 p.m. CDT - "A randomized, double-blind, placebo-controlled, multi-center, phase III trial of sipuleucel-T in men with metastatic, androgen independent prostatic adenocarcinoma (AIPC)." AUA Late-Breaking Science Forum to be held from 1:00 p.m. to 2:30 p.m. CDT. Room W375 at McCormick Place
  • April 28, 2009, 10:30 a.m. to 12:30 p.m. CDT - Abstract #1408: "Preclinical Evaluation of the TRPM8 Ion Channel Agonist D-3263 for Benign Prostatic Hyperplasia." Poster presentation to occur in the Benign Prostatic Hyperplasia: Basic Research session. Room W375B at McCormick Place
  • April 28, 2009, 4:30 p.m. CDT - IMPACT data webcast conference call

The IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) study evaluated PROVENGE(R) (sipuleucel-T), Dendreon's investigational product candidate for men with advanced prostate cancer representing the first in a new class of active cellular immunotherapies specifically designed to engage the patient's own immune system against cancer. Dendreon announced last week that the IMPACT trial met its primary endpoint of improving overall survival compared to a placebo control.

To access the live conference call, dial 1-877-675-4753 (domestic) or 719-325-4864 (international). The call also will be audio webcast and will be available from the Company's website at www.dendreon.com under the "Investor/Webcast
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
2. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
3. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
4. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
5. Dendreon Reports Third Quarter 2008 Financial Results
6. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
7. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
8. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
9. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
10. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
11. Dendreon Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... (Nasdaq: VIAP ), a biotechnology company focused on ... and metabolic disease, today announced that it has completed ... clinical trial of VIA-2291. ,, The FDG-PET trial ... sites in the US and Canada including Massachusetts General ...
(Date:12/3/2009)... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that ... of fiscal year 2010 on December 10, 2009 at 7:00 ... to discuss the results at 11:30 a.m. EST on the ... for the second quarter ended October 31, 2009 and will ...
(Date:12/3/2009)... Sciences, Inc. (Nasdaq: CALP ), a leading provider ... sciences research, today introduced Living Image 4.0 software for ... the more than 800 Caliper IVIS systems currently installed ... unmixing tools to enhance fluorescent sensitivity and automated 3D ...
(Date:12/2/2009)... MATK ) announced today that it intends to release ... on December 16, 2009, at approximately 4:00 p.m. Eastern Time ... will conduct a conference call to discuss these results with ... live via webcast by visiting Martek,s web site at ...
Breaking Biology Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2Caliper Life Sciences Launches Living Image(R) 4.0 Software 2Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2
... MOUNTAIN VIEW, Calif., May 13 Based on ... & Sullivan recognizes Precision Biosciences with the 2009 ... Innovation of the Year. The company,s radical Directed ... and modify regions of a cell,s genome with ...
... 12 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) ... on Tuesday, May 19, 2009 at 11:30 a.m. ... Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will ... be webcast, and a recording will be made available following ...
... 12 Masimo Corporation (Nasdaq: MASI ), the ... oximetry, today announced that its management is scheduled to present ... Boston, Massachusetts, on Tuesday, May 19, 2009, at 2:35 p.m. ... available on the Masimo website at www.masimo.com . ...
Other Biology Technology:Frost & Sullivan Awards Precision Biosciences for Technology Innovation and Molecular Design Process in the Genomics Market 2Frost & Sullivan Awards Precision Biosciences for Technology Innovation and Molecular Design Process in the Genomics Market 3Frost & Sullivan Awards Precision Biosciences for Technology Innovation and Molecular Design Process in the Genomics Market 4Masimo to Present at the Deutsche Bank 34th Annual Health Care Conference 2
(Date:12/4/2009)... activity in organs relevant for coronary artery disease (CAD), ... identified a module of genes that is important for ... plaque. The findings, which are to be published in ... targeting the migration of white blood cells in the ...
(Date:12/4/2009)... Using a new mathematical model of heart cells, University ... critical enzyme, calmodulin kinase II (CaM kinase), disrupts the ... study, which also involved Columbia University, was published online ... . , "Recently, researchers have developed great interest ...
(Date:12/3/2009)... changes in our daily environment, as well as to retain ... nerve cells communicate, according to a new study by NYU ... week in the journal Nature . , The ... and neuroscience at NYU School of Medicine, discovered that a ...
Breaking Biology News(10 mins):Scientists discover gene module underlying atherosclerosis development 2U-Iowa study helps advance heart-related research 2Lifelong memories linked to stable nerve connections 2PAREXEL Experts to Present Leading Insights at Drug Information Association Annual Clinical Forum 59729 1PAREXEL Experts to Present Leading Insights at Drug Information Association Annual Clinical Forum 59729 2PAREXEL Experts to Present Leading Insights at Drug Information Association Annual Clinical Forum 59729 3PAREXEL Experts to Present Leading Insights at Drug Information Association Annual Clinical Forum 59729 4Lubris Biomodels Report on Potential New Therapy for Osteoarthritis 14521 1Lubris Biomodels Report on Potential New Therapy for Osteoarthritis 14521 2NovaBay Pharmaceuticals Expands Management Team 3B Names Mark Anderson Ph D as Chief Scientific Officer 5549 1NovaBay Pharmaceuticals Expands Management Team 3B Names Mark Anderson Ph D as Chief Scientific Officer 5549 2NovaBay Pharmaceuticals Expands Management Team 3B Names Mark Anderson Ph D as Chief Scientific Officer 5549 3
... you make for your child could well be a ring ... help the plant produce cyanide to protect itself against ... clover. Other clover plants that do not make cyanide are ... poison, er, clover, ecology and geography play important roles. ...
... pretzel factory production line, with conveyer belts carrying the dough, formed ... , Now imagine what would happen if pretzel dough started to ... misshapen, and sticking fast to the dough of the other fully ... could no longer be conveyed into the oven, the backup of ...
... p.m. , The New York Academy of Sciences, 7 ... York, NY 10007 , The Malaria Research Institute at ... The New York Academy of Sciences present Progress Against ... highlight the latest research developments in the fight to ...
Other Biology News:Genetic differences in clover make one type toxic 2Genetic differences in clover make one type toxic 3Botched production of insulin molecule may lead to diabetes 2Botched production of insulin molecule may lead to diabetes 3Botched production of insulin molecule may lead to diabetes 4Progress Against Malaria: Developments on the Horizon 2
Rabbit polyclonal to Methionine Aminopeptidase 2 ( Abpromise for all tested applications). entrezGeneID: 10988 SwissProtID: P50579...
Anti-gp340 Monoclonal Antibody Description: 100 g Research Focus: cancer & cell proliferation Storage: -20C Shipping Temperature: 4C...
Sheep polyclonal to Methaqualone ( Abpromise for all tested applications). Antigen: Methaqualone(5') conjugated to BSA...
Prostaglandin-E2 receptor EP2/EP3 Market Segment: GPCRs...
Biology Products: